Antibody Drug Conjugates Market

Antibody Drug Conjugates Market Driven by
Extensive Research and Development Activities Top
Players Are Hoffmann-La Roche Ltd, , GE
Healthcare
Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad
therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to
mark and kill only cancer cells. Antibody drug conjugates are compound molecules that
comprise antibodies linked to a biologically active cytotoxic drug.
Request Sample Copy of Research Report @ https://bit.ly/2GYVBLB
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for
subtle judgment between healthy and diseased tissue. This entails that the antibody drug
conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected.
This exceptional phenomenon of killing only cancer cells increase the importance of use of
ADCs, which would indirectly boost growth of the global antibody drug conjugates market.
Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to
over US$ 10 billion over the forecast period of market
In terms of marketing, three antibody drug conjugates have received regulatory approval. The
U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to
treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving
only two antibody drug conjugates in the market. The two drugs marketed for ADCs are
Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle
Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody
drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a
high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development.
Frequently used cytotoxins for antibody drug conjugates under trials include auristatin,
calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting
for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds
under clinical trials, and this is the most developed pipeline of antibody drug conjugates.
Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There
are limited number of contract manufacturers that have high-end manufacturing equipment for
development of cytotoxins.
Report includes chapters which deeply display the following deliverable about industry :
• Antibody Drug Conjugates Market Research Objective and Assumption
• Antibody Drug Conjugates Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Antibody Drug Conjugates Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Antibody Drug Conjugates Market, By Regions
• Antibody Drug Conjugates Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Antibody Drug Conjugates Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Antibody Drug Conjugates Market Manufacturing Cost Analysis including Key Raw Materials
and Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Antibody Drug Conjugates Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the
market to two digit billion dollar mark by 2020
The global antibody drug conjugates market is segmented on the basis of drug and geography.
On the basis of drug, the market is divided into Adcetris and Kadcyla.
Major pharmaceutical company opt for contract manufacturer for development and manufacture
of antibody drug conjugates
Regional segmentation of the antibody drug conjugates market by Coherent Market Insights
comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe
accounts for the largest share in the global market mainly due to presence of many contract
manufacturing companies with advanced manufacturing equipment. Lonza is one of the top
contract manufacturing companies in Europe, which has operations across France and Germany,
with its headquarters in Switzerland. One of the facilities operated by the company is a deck
to chemical manufacturing capabilities and develop peptides, small molecule active
pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents,
antibody drug conjugates, and microbial products. The company also offer proficiency in
chemical, pharmaceutical, agrochemical and food industries by providing clients with yields
such as high-class active substances, organic chemicals and intermediates.
Request For Customization of Research Report @ https://bit.ly/2SIzx9t
Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates
market
Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd,
Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics,
Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates
industry are constantly working on research and development, as the market is largely untapped
and offer highly lucrative growth opportunities. For instance, there are only two antibody drug
conjugates available worldwide that are used to treat cancer, and there are over 40 molecules
under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe,
the antibody conjugates market is expected to ride on a wave of positive growth in the
foreseeable future.
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars,
called PHASE-XS. This database provides analytical data in addition to the clinical information
of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters,
PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend,
competition, and market potential. For more information or to access this database, kindly click
on the below link or contact at sales@coherentmarketinsights.com
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer.

Download Report